stock decline

Perfect Moment stock tumbles 11.21% after hours despite announcing $12M financing, with luxury brand down 78.97% annually amid persistent investor concerns.

Federal securities class action filed against $SNOW for allegedly misleading statements about product efficiency. Stock fell 18.14% after disappointing February 2024 earnings disclosure.

Lakeland Industries faces securities fraud lawsuit alleging it overstated Pacific Helmets and Jolly business performance while concealing operational issues. Stock has declined 60%.

Class action lawsuit filed against Navan alleges IPO documents omitted increased marketing spend and slowing revenue. Stock fell 11.89% after Q1 loss.

Beyond Meat stock plunged 10.6% after reporting Q4 losses and Q1 guidance missing expectations, with stock trading below $1 risking delisting compliance.

Nike stock crashed 15.1% after weak forward guidance, with Q4 sales expected to decline 2-4% and Greater China revenue dropping 20%.

Cybersecurity stocks down sharply on AI concerns, but insider buying at $PANW and vesting-driven selling at $CRWD and $RBK suggest mixed sentiment.

BigBear.ai stock has declined significantly, but stronger financials, massive backlog, and policy tailwinds could drive future growth, suggesting potential oversold conditions.

Nike reports flat Q3 revenue at $11.28B and 23% operating income decline. Stock drops 9% as tariffs and inventory challenges delay margin recovery until Q2 2027.

uniQure's stock plummeted 49% after FDA rejected its AMT-130 drug candidate; securities fraud lawsuit filed for alleged failure to disclose approval risks during September-October 2025.

ImmunityBio faces securities fraud lawsuit following FDA warning letter about Anktiva cancer therapy misleading ads. Stock plummeted to $7.42.

Trip.com faces securities fraud class action after China's antitrust regulator probes alleged monopolistic practices. Stock fell 19.4% in January 2026.

Driven Brands ($DRVN) stock crashed 40% after disclosing material financial statement errors spanning 2023-2025, triggering securities fraud class action litigation.

Corcept Therapeutics faces securities class action after FDA rejected relacorilant, causing 50% stock collapse. Investors have until April 21 to file claims.

Ulta Beauty stock down 10% in 2026 as company pursues strategic repositioning. The decline raises questions about whether current valuations present a buying opportunity amid broader beauty retail sector challenges.

Pomerantz LLP sues Soleno Therapeutics ($SLNO) over alleged securities fraud as stock plummets 39% following DCCR safety concerns and patient death disclosure. Lead Plaintiff deadline: May 5, 2026.

Aldeyra Therapeutics stock plummets 71% following FDA rejection of reproxalap for dry eye disease. Class action lawsuit filed; investor deadline May 29, 2026.

Class action lawsuit alleges $ORCL concealed massive CapEx increases and associated risks amid AI infrastructure expansion, following analyst downgrades and disappointing results.

Plug Power faces class action lawsuit deadline this Friday over alleged misstatements about DOE loan program and hydrogen strategy during 2025.

Kessler Topaz files class action against $ORCL alleging material misstatements about AI capabilities and CapEx between June-December 2025. Lead plaintiff deadline set for April 6, 2026.